- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01611688
First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis
February 23, 2017 updated by: Novo Nordisk A/S
This trial is conducted in Europe.
The aim of this trial is to describe the safety and tolerability of single intravenous (i.v.) and subcutaneous (s.c.) doses of NNC0215-0384 in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening
- Concomitant treatment with MTX (7.5 - 25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing
Exclusion Criteria:
- Subjects with chronic inflammatory autoimmune disease other than RA
- History of or current inflammatory joint disease other than RA such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or Lyme disease
- Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to randomisation
- Clinically significant cardiac or cardiovascular disease
- Past or current malignancy
- Latent or active tuberculosis (TB) as documented by: A positive QuantiFeron® test (test can be performed up to 2 months prior to dosing). One retest is allowed in case of inconclusive results.- A history of active TB within the last 3 years even, if treated effectively. - A history of active TB more than 3 years ago, if there is no documentation that the prior anti-TB treatment was appropriate in duration and type
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Administered i.v.(intravenous) or s.c.
(subcutaneous, under the skin).
|
|
EXPERIMENTAL: Active
|
I.v.(intravenous) dose-escalation.
Highest dose planned for i.v.
administration is 10 mg/kg
The s.c.
(subcutaneous, under the skin) part will not start until at least two i.v.
dose levels have been evaluated for safety and pharmacokinetics.
Highest dose planned for s.c.
administration is 4 mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of adverse events (AEs)
Time Frame: Up to 10 weeks after trial product administration
|
Up to 10 weeks after trial product administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
I.v. administration: AUC, Area under the curve
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
I.v. administration: terminal half-life (t½)
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
S.c. administration: AUC, Area under the curve
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
S.c. administration: terminal half-life (t½)
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
Maximum level and duration of full C5a receptor (C5aR) occupancy by NNC0215-0384 on neutrophils
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
Maximum and minimum levels of relevant serum and plasma biomarkers related to NNC0215-0384 safety, efficacy or mechanism of action (MoA)
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 4, 2012
Primary Completion (ACTUAL)
June 17, 2013
Study Completion (ACTUAL)
June 17, 2013
Study Registration Dates
First Submitted
June 1, 2012
First Submitted That Met QC Criteria
June 1, 2012
First Posted (ESTIMATE)
June 5, 2012
Study Record Updates
Last Update Posted (ACTUAL)
February 27, 2017
Last Update Submitted That Met QC Criteria
February 23, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN8210-3926
- 2011-003008-19 (EUDRACT_NUMBER)
- U1111-1122-3474 (OTHER: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.